Associations - PD-L1 overexpression

BIOMARKER:

PD-L1 overexpression

Entrez ID:

29126

Related biomarkers:

‹

›

PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	pembrolizumab Sensitive: A2 - Guideline J Clin Oncol - 2 weeks pembrolizumab Sensitive : A2 J Clin Oncol - 2wk
PD-L1 overexpression PD-L1 overexpression	Thyroid Gland Anaplastic Carcinoma Thyroid Gland Anaplastic Carcinoma	anlotinib + sintilimab Sensitive: C4 – Case Studies Onco Targets Ther - 2 weeks anlotinib + sintilimab Sensitive : C4 Onco Targets Ther - 2wk
PD-L1 overexpression PD-L1 overexpression	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	Immunotherapy Sensitive: C3 – Early Trials Lung Cancer - 3 weeks Immunotherapy Sensitive : C3 Lung Cancer - 3wk
PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	cemiplimab Sensitive: A1 - Approval cemiplimab Sensitive : C1
PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : C1
PD-L1 overexpression PD-L1 overexpression	Urothelial Cancer Urothelial Cancer	tislelizumab Sensitive: A1 - Approval tislelizumab Sensitive : C1
PD-L1 overexpression PD-L1 overexpression	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	bevacizumab + atezolizumab Sensitive: A2 - Guideline bevacizumab + atezolizumab Sensitive : A2
PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	bevacizumab Sensitive: A2 - Guideline bevacizumab Sensitive : A2
PD-L1 overexpression PD-L1 overexpression	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	atezolizumab Sensitive: A2 - Guideline atezolizumab Sensitive : C1
PD-L1 overexpression PD-L1 overexpression	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
PD-L1 overexpression PD-L1 overexpression	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	nivolumab + ipilimumab Sensitive: A2 - Guideline nivolumab + ipilimumab Sensitive : A2
PD-L1 overexpression PD-L1 overexpression	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	cemiplimab Sensitive: A2 - Guideline cemiplimab Sensitive : C1
PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	atezolizumab + MTIG7192A Sensitive: B - Late Trials atezolizumab + MTIG7192A Sensitive : B
PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	carboplatin + albumin-bound paclitaxel Sensitive: B - Late Trials carboplatin + albumin-bound paclitaxel Sensitive : B
PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	carboplatin + gemcitabine Sensitive: B - Late Trials carboplatin + gemcitabine Sensitive : B
PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	cisplatin + albumin-bound paclitaxel Sensitive: B - Late Trials cisplatin + albumin-bound paclitaxel Sensitive : B
PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	GC Sensitive: B - Late Trials GC Sensitive : B
PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	carboplatin + pemetrexed Sensitive: B - Late Trials carboplatin + pemetrexed Sensitive : B
PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	cisplatin + pemetrexed Sensitive: B - Late Trials cisplatin + pemetrexed Sensitive : B
PD-L1 overexpression PD-L1 overexpression	GastroEsophageal Cancer GastroEsophageal Cancer	PD1 inhibitor Sensitive: B - Late Trials PD1 inhibitor Sensitive : B
PD-L1 overexpression PD-L1 overexpression	GastroEsophageal Cancer GastroEsophageal Cancer	PD-L1 inhibitor Sensitive: B - Late Trials PD-L1 inhibitor Sensitive : B
PD-L1 overexpression PD-L1 overexpression	Triple Negative Breast Cancer Triple Negative Breast Cancer	pembrolizumab Sensitive: B - Late Trials pembrolizumab Sensitive : B
PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	tislelizumab Sensitive: B - Late Trials tislelizumab Sensitive : C1
PD-L1 overexpression PD-L1 overexpression	Urothelial Cancer Urothelial Cancer	durvalumab Sensitive: B - Late Trials durvalumab Sensitive : B
PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	nivolumab Sensitive: B - Late Trials nivolumab Sensitive : B
PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	avelumab Sensitive: B - Late Trials avelumab Sensitive : B

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES